Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.
NAFLD
NASH
anxiety disorder
depression
metabolic inflammation
metabolic syndrome
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
24
7
2020
medline:
13
7
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. Its role in the development of extrahepatic co-morbidities is under investigation. The impact of NAFLD on the development of chronic kidney disease (CKD) is incompletely understood. The aim of this study was to explore the potential contribution of NAFLD on CKD in Germany. The Disease Analyzer Database covering 7.49 million cases in Germany was explored for patients diagnosed with NAFLD between 2000 and 2015 and was matched 1:1 to a cohort without NAFLD. Matching criteria included age, sex, physician, index year and co-diagnoses associated with CKD. The primary outcomes of this study were incidences of CKD and end-stage renal disease. A total of 48,057 patients with NAFLD were matched to 48,057 patients without NAFLD. Within 10 years of the index date, 17.1% of patients with NAFLD and 11.6% of patients without NAFLD were diagnosed with CKD ( In this large database analysis in Germany, NAFLD constitutes an independent risk factor for CKD. Patients living with NAFLD should be monitored for a change in kidney function, facilitating therapeutic measures for kidney disease at an early stage.
Sections du résumé
BACKGROUND AND AIM
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. Its role in the development of extrahepatic co-morbidities is under investigation. The impact of NAFLD on the development of chronic kidney disease (CKD) is incompletely understood. The aim of this study was to explore the potential contribution of NAFLD on CKD in Germany.
METHODS
The Disease Analyzer Database covering 7.49 million cases in Germany was explored for patients diagnosed with NAFLD between 2000 and 2015 and was matched 1:1 to a cohort without NAFLD. Matching criteria included age, sex, physician, index year and co-diagnoses associated with CKD. The primary outcomes of this study were incidences of CKD and end-stage renal disease.
RESULTS
A total of 48,057 patients with NAFLD were matched to 48,057 patients without NAFLD. Within 10 years of the index date, 17.1% of patients with NAFLD and 11.6% of patients without NAFLD were diagnosed with CKD (
CONCLUSIONS
In this large database analysis in Germany, NAFLD constitutes an independent risk factor for CKD. Patients living with NAFLD should be monitored for a change in kidney function, facilitating therapeutic measures for kidney disease at an early stage.
Identifiants
pubmed: 32698692
doi: 10.1177/2050640620944098
pmc: PMC7707877
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
942-948Références
Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1
pubmed: 30580090
Pharmaceuticals (Basel). 2018 Oct 11;11(4):
pubmed: 30314377
Lancet. 2019 Dec 14;394(10215):2131-2133
pubmed: 31813639
Gastroenterology. 2020 May;158(7):1929-1947.e6
pubmed: 32068022
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
J Hepatol. 2017 Dec;67(6):1274-1280
pubmed: 28870674
Am J Kidney Dis. 2014 Oct;64(4):638-52
pubmed: 25085644
Diabetes Obes Metab. 2020 Sep;22(9):1607-1618
pubmed: 32363737
Lancet Diabetes Endocrinol. 2014 May;2(5):417-26
pubmed: 24795255
Metabolism. 2011 May;60(5):735-9
pubmed: 20817213
Hepatology. 2011 Oct;54(4):1454-62
pubmed: 21725995
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
J Hepatol. 2020 Apr;72(4):785-801
pubmed: 32059982
Bratisl Lek Listy. 2020;121(5):348-351
pubmed: 32437208
J Hepatol. 2020 Sep;73(3):680-693
pubmed: 32353483
Hepatol Commun. 2019 Sep 30;3(11):1472-1481
pubmed: 31701071
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76
pubmed: 23855299
Metabolism. 2018 Feb;79:64-76
pubmed: 29137912
Dig Dis Sci. 2020 Jul;65(7):2112-2119
pubmed: 31797186